Transgenomic has selected two distributors to supply its ICEme Mutation Enrichment Kits in China and Japan.
Spectron Scientific will distribute the kits in China, while Sowa Trading will take the responsibility to supply kits in Japan.
Through using the firm’s Multiplexed ICE COLD-PCR (MX-ICP) technology, the kits will facilitate genomics-based cancer research.
Transgenomic president and CEO Paul Kinnon said: "Asia represents important and growing markets for cancer research, and our ICEme Kits will allow researchers in China and Japan to use the sequencing platforms already in their labs to conduct sophisticated genetic analyses to accelerate their cancer research and drug discovery programs.
"We expect to announce additional distributors in other key territories soon."
ICEme Kits are said to work with most patient samples, including tissue, blood, plasma, urine and other biofluids, as well as they can be easily customizable for use with single mutations or in combination.
The initial menu comprises 17 clinically relevant and actionable mutations, which are associated with important cancers such as colorectal, lung and breast cancer, and melanoma.